Tag Archives: Amarin

Cantor Fitzgerald Keeps a Buy Rating on Amarin (AMRN)

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amarin (AMRN – Research Report), with a price target of $35. The company’s shares closed yesterday at $13.59. Chen commented: “We think the peak sales

Amarin (AMRN) Receives a Buy from Cantor Fitzgerald

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amarin (AMRN – Research Report), with a price target of $35. The company’s shares opened today at $15.68. Chen noted: “We think the peak sales

Analysts Conflicted on These Healthcare Names: Amarin (NASDAQ: AMRN) and Amneal Pharmaceuticals Inc (NYSE: AMRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amarin (AMRN – Research Report) and Amneal Pharmaceuticals Inc (AMRX – Research Report). Amarin (AMRN) Cantor Fitzgerald analyst Louise Chen maintained a Buy

Cantor Fitzgerald Maintains a Buy Rating on Amarin (AMRN)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Amarin (AMRN – Research Report) today and set a price target of $35. The company’s shares closed yesterday at $17.99. Chen noted: “We think the peak sales potential of Vascepa

Analysts Offer Insights on Healthcare Companies: Amarin (NASDAQ: AMRN), Pluristem (NASDAQ: PSTI) and Biospecifics Technologies Corp (NASDAQ: BSTC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN – Research Report), Pluristem (PSTI – Research Report) and Biospecifics Technologies Corp (BSTC – Research Report) with bullish sentiments. Amarin

H.C. Wainwright Sticks to Its Buy Rating for Amarin (AMRN)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Amarin (NASDAQ: AMRN), with a price target of $31. The company’s shares closed yesterday at $22.64, close to its 52-week high of $23.10. Fein said: